Home
Clinical Trials
A Randomized Trial of Delayed...

A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery

Last Updated: 2026-01-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

280 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-12-07

Study Completion Date

2030-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Because of their prolonged survival, patients with 1p/19q-codeleted low-grade oligodendrogliomas treated with RT + PCV are at risk of neurocognitive deterioration. We make the hypothesis that withholding radiotherapy until tumor progression could reduce the risk of neurocognitive deterioration without impairing overall survival.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

gliomasPCV Only in 1p/19q Codeleted Anaplastic Gliomas

NCT02444000

Anaplastic Gliomas With 1p/19q Codeletion

COMPLETED PHASE3

Phase III Study Comparing 2 Brain Conformational Radiotherapy in Combination With Chemotherapy in the Treatment of Glioblastoma

NCT01507506

Glioblastoma

TERMINATED PHASE3

Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (310 Gy) to the Historical Single-dose Radiosurgery (120 to 25 Gy) With Medico-economic Evaluation.

NCT05102747

Brain Metastasis Oligoprogression

RECRUITING NA

Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma

NCT01165333

Diffuse Intrinsic Pontine Glioma

COMPLETED PHASE1

Radiotherapy for Malignant Astrocytomas in the Elderly

NCT00430911

Primary Brain Tumor Anaplastic Astrocytoma Glioblastoma Multiforme

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oligodendroglioma Low-grade Oligodendroglioma 1p19q Codeletion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PCV alone

Administration of 6 cycles of PCV chemotherapy alone.

Group Type EXPERIMENTAL

PCV chemotherapy

Intervention Type DRUG

1. cycle of PCV chemotherapy is given as:

* Day 1: CCNU 110 mg/m2 orally;
* Days 8 and 29: Vincristine 1.4 mg/m2 IV;
* Days 8 to 21: Procarbazine 60 mg/m2 orally

6 cycles are given.

RT + PCV

Radiotherapy followed by administration of PCV chemotherapy.

Group Type ACTIVE_COMPARATOR

Radiotherapy and PCV chemotherapy

Intervention Type DRUG

Radiotherapy will deliver 50.4 Gy in 28 fractions of 1.8 Gy using IMRT technique.

Followed by 6 cycles of PCV chemotherapy

1 cycle of PCV is given as:

* Day 1: CCNU 110 mg/m2 orally;
* Days 8 and 29: Vincristine 1.4 mg/m2 IV;
* Days 8 to 21: Procarbazine 60 mg/m2 orally

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PCV chemotherapy

1. cycle of PCV chemotherapy is given as:

* Day 1: CCNU 110 mg/m2 orally;
* Days 8 and 29: Vincristine 1.4 mg/m2 IV;
* Days 8 to 21: Procarbazine 60 mg/m2 orally

6 cycles are given.

Intervention Type DRUG

Radiotherapy and PCV chemotherapy

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Tumor is co-deleted for 1p and 19q based and IDH-mutant (IDH1 or IDH2) according to local diagnosis
* Histological confirmation of low-grade oligodendroglioma by central pathological review according to WHO 2016 classification
* Age ≥ 18 years
* Patients with one or several prior surgical procedure for a low-grade oligodendroglioma and who undergo a resurgery are eligible if they have not received prior radiotheray or chemotherapy and if the last histological diagnosis is a low-grade oligodendroglioma prior use of specific HDI prohibitions is permitted
* Patients who undergo an initial follow-up after surgery or re-surgery are eligible if there is no evidence of anaplastic transformation on MRI (no new contrast enhancement, no obvious modification of the growth rate)
* Patients requiring an oncological treatment other than surgery because of one or more of the following characteristics:

* Progressive disease defined as documented growth prior to inclusion
* Symptomatic disease defined as the presence of neurological or cognitive symptoms or refractory seizures defined as having both persistent seizures interfering with everyday life activities other than driving a car and three lines of anti-epileptic drug regimen had not worked, including at least one combination regimen.
* Age ≥ 40 and any surgical therapy
* Age \< 40 with prior and subtotal resection or biopsy (i.e., anything less than gross total resection)
* Willing and able to complete neurocognitive examination and the QOL
* Karnofsky performance status ≥ 60
* Laboratory values obtained between 21 days before inclusion andrandomization, respecting the following criteria:
* Absolute neutrophil count (ANC) ≥1500 /mm3
* Platelet count ≥100,000 / mm3
* Hemoglobin \> 9.0 g/dL
* Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
* SGOT (AST) ≤ 3 x ULN
* Negative serum or urine pregnancy test done ≤ 7 days prior to registration, for women of childbearing potential only.
* Provide informed written consent

Exclusion Criteria

* Pregnant and nursing women
* Men or women of childbearing potential who are unwilling to employ adequate contraception for up to 6 months following the completion of PCV.
* Received any prior radiation therapy or chemotherapy for any CNS neoplasm.
* Co-morbid systemic illnesses or other severe concurrent disease which would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
* Concomitant serious immunocompromised status (other than that related to concomitant steroids).
* Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements.
* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm (except specific inhibitors of IDH)
* Other active malignancy within 5 years of registration. Exceptions: Non-melanotic skin cancer or carcinoma-in-situ of the cervix.
* Contra-indication to CCNU: hypersensitivity to CCNU, wheat allergy, association to yellow fever vaccin
* Contra-indication to Procarbazine: severe renal failure, severe hepatic failure, hypersensitivity to procarbazine, association to yellow fever vaccin
* Contra-indication to Vincristine: hypersensitivity to vincristine, neuromuscular disorder (for example demyelinating Charcot-Mary Tooth neuropathy), severe renal failure, severe hepatic failure.
* Not depending from the french system of health assurance

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers